Fanconi Anemia Gene Mutations in Young-onset Pancreatic Cancer

Michiel S. van der Heijden, Charles J. Yeo, Ralph H. Hruban, and Scott E. Kern

Departments of Oncology [M. S. v. d. H., S. E. K., R. H. H.], Pathology [R. H. H., S. E. K.], and Surgery [C. J. Y.], The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231

ABSTRACT

Genes of the Fanconi complementation groups [Fanconi anemia (FA) genes] are suggested to be involved in homologous DNA recombination and produce FA when two allelic mutations are inherited. BRCA2 is an FA gene and additionally conveys an inherited risk for breast, ovarian, and pancreatic cancer for individuals carrying a single mutated allele [N. G. Howlett et al., Science (Wash. DC), 297: 606–609, 2002]. Here we report inherited and somatic mutations of FANCC and FANCG present in young-onset pancreatic cancer. This may imply a general involvement of Fanconi genes with an inherited risk of cancer. The known hypersensitivity of Fanconi cells to mitomycin and other therapeutic agents [M. S. Sasaki, Nature (Lond.), 297: 501–503, 1975] suggests a therapeutic utility for a more complete characterization of the DNA repair defects and their causative genetic mutations in pancreatic cancer.

INTRODUCTION

FA3 is an inherited autosomal recessive syndrome, characterized cellularly by hypersensitivity to cross-linking agents such as mitomycin C. Patients often present with congenital bone deformities and bone marrow failure and are highly susceptible to the occurrence of hematological tumors (especially acute myelogenous leukemia) and squamous cell tumors of the head and neck, gynecological system, and other organs. Recently, BRCA2 mutations have been shown to be responsible for a subset of FA patients, complementation group D1. Cells from these patients were recently reported to be complex heterogeneous, containing both hypomorphic and nonfunctional alleles of BRCA2; complementation of such cells with wild-type BRCA2 cDNA restored resistance to mitomycin C (1, 2). Among human tumors, pancreatic cancers harbor the highest prevalence of BRCA2 mutations, which are present in 7–10% of “sporadic” pancreatic cancers (those with a family history negative for cancer) and 17% of families with a strong history of the disease [kindred with ≥3 family members affected, including at least 2 first-degree relatives (3–6)]. As is BRCA2, the FANCC and FANCG genes are the sites of additional FA gene mutations carried in the general population. To help understand the potential inherited basis of pancreatic cancer, we determined whether inactivating FANCC and FANCG gene mutations might occur as homozygous mutations in pancreatic cancers.

MATERIALS AND METHODS

Cancers of the pancreas and distal common bile duct resected at the Johns Hopkins Hospital between 1992 and 1997 were expanded as xenografts in 22 tumors selected for LOH at 9q22.3 and 11 unselected pancreatic cancer cell lines (BxPC3, AsPC1, CAPAN1, CAPAN2, MiaPaCa2, Panc-1, Hs766T, CFPAC1, Su86.86, PL9, and PL45) obtained from the American Type Culture Collection (Manassas, VA) and European Collection of Animal Cell Cultures (Salisbury, United Kingdom). FANCC was sequenced in 22 tumors selected for LOH at 9p13.1 and the same 11 cell lines used for FANCC.

All exons were amplified and sequenced from genomic DNA. Mutations were confirmed by sequencing of independent PCR products and confirmed in case PX19 by analysis of two xenografts derived independently from the same primary tumor. Constitutional DNA, where available, was sequenced to determine whether the alterations were somatic or germ-line in origin. FANCC exons were amplified using the following PCR primers: (a) 5'-AGAGGCTTCTTAGAATGTCCT and 5'-CCTGACTGACAGCAAGAGTTTTATTGTAG and 5'-TACGTGCTTCAAGCATTAG and 5'-TGCAGACACATCAGTATAG, exon 1; (b) 5'-CCACATTTAGAAGGATGGAAGTTTTTTGTGGTGGAGGGATGATTTTC and 5'-AAACACCATCATTCTCAT-TAAT, exon 5 and 5'-TGTTCTGAGAGTCAAGCTAAGTTG and 5'-TGGTTCTGAGAGTCAAGCTAAGTTG; (c) 5'-CCTGACTGACAGCAAGAGTTTTATTGTAG and 5'-TACGTGCTTCAAGCATTAG and 5'-TGCAGACACATCAGTATAG, exon 2; (c) 5'-TACGTGCTTCAAGCATTAG and 5'-TGCAGACACATCAGTATAG, exon 3; (d) 5'-CCTGACTGACAGCAAGAGTTTTATTGTAG and 5'-TACGTGCTTCAAGCATTAG and 5'-TGCAGACACATCAGTATAG, exon 4; (e) 5'-CCTGACTGACAGCAAGAGTTTTATTGTAG and 5'-TACGTGCTTCAAGCATTAG and 5'-TGCAGACACATCAGTATAG, exon 5; (f) 5'-TGCAGACACATCAGTATAG and 5'-TGCAGACACATCAGTATAG; (g) 5'-TGCAGACACATCAGTATAG and 5'-TGCAGACACATCAGTATAG, exon 6; (h) 5'-TGCAGACACATCAGTATAG and 5'-TGCAGACACATCAGTATAG; (i) 5'-TGCAGACACATCAGTATAG and 5'-TGCAGACACATCAGTATAG, exon 7; (j) 5'-TGCAGACACATCAGTATAG and 5'-TGCAGACACATCAGTATAG, exon 8; (k) 5'-TGCAGACACATCAGTATAG and 5'-TGCAGACACATCAGTATAG, exon 9.

The following PCR primers were used for FANCG: (a) 5'-TGCAGACACATCAGTATAG and 5'-TGCAGACACATCAGTATAG, exon 1; (b) 5'-TGCAGACACATCAGTATAG and 5'-TGCAGACACATCAGTATAG, exon 2; (c) 5'-TGCAGACACATCAGTATAG and 5'-TGCAGACACATCAGTATAG, exon 3; (d) 5'-TGCAGACACATCAGTATAG and 5'-TGCAGACACATCAGTATAG, exon 4; (e) 5'-TGCAGACACATCAGTATAG and 5'-TGCAGACACATCAGTATAG, exon 5; (f) 5'-TGCAGACACATCAGTATAG and 5'-TGCAGACACATCAGTATAG, exon 6; (g) 5'-TGCAGACACATCAGTATAG and 5'-TGCAGACACATCAGTATAG, exon 7; (h) 5'-TGCAGACACATCAGTATAG and 5'-TGCAGACACATCAGTATAG, exon 8; (i) 5'-TGCAGACACATCAGTATAG and 5'-TGCAGACACATCAGTATAG, exon 9; (j) 5'-TGCAGACACATCAGTATAG and 5'-TGCAGACACATCAGTATAG, exon 10; (k) 5'-TGCAGACACATCAGTATAG and 5'-TGCAGACACATCAGTATAG, exon 11; (l) 5'-TGCAGACACATCAGTATAG and 5'-TGCAGACACATCAGTATAG, exon 12.

The following PCR primers were used for FANCG: (a) 5'-TGCAGACACATCAGTATAG and 5'-TGCAGACACATCAGTATAG, exon 1; (b) 5'-TGCAGACACATCAGTATAG and 5'-TGCAGACACATCAGTATAG, exon 2; (c) 5'-TGCAGACACATCAGTATAG and 5'-TGCAGACACATCAGTATAG, exon 3; (d) 5'-TGCAGACACATCAGTATAG and 5'-TGCAGACACATCAGTATAG, exon 4; (e) 5'-TGCAGACACATCAGTATAG and 5'-TGCAGACACATCAGTATAG, exon 5; (f) 5'-TGCAGACACATCAGTATAG and 5'-TGCAGACACATCAGTATAG, exon 6; (g) 5'-TGCAGACACATCAGTATAG and 5'-TGCAGACACATCAGTATAG, exon 7; (h) 5'-TGCAGACACATCAGTATAG and 5'-TGCAGACACATCAGTATAG, exon 8; (i) 5'-TGCAGACACATCAGTATAG and 5'-TGCAGACACATCAGTATAG, exon 9; (j) 5'-TGCAGACACATCAGTATAG and 5'-TGCAGACACATCAGTATAG, exon 10; (k) 5'-TGCAGACACATCAGTATAG and 5'-TGCAGACACATCAGTATAG, exon 11; (l) 5'-TGCAGACACATCAGTATAG and 5'-TGCAGACACATCAGTATAG, exon 12.

RESULTS AND DISCUSSION

Disease-inducing intragenic BRCA2 mutations in pancreatic cancer are uniformly accompanied by loss of the wild-type allele (4); we therefore studied conventional (“sporadic”) ductal pancreatic adenocarcinomas that had LOH at 9q22.3 (FANCC) and 9p13 (FANCG). Three homozygous variants were observed: one in FANCC; and two in FANCG (Table 1; Fig. 1). Specifically, a deletion of 5 bp (nucleotides 1903–1907; National Center for Biotechnology Information) was observed in exon 14 of FANCC, resulting in a frameshift alteration. Upon comparison with the nonneoplastic DNA of this patient, this mutation was found to be somatic. The other FANCC mutation was a germ-line missense mutation in exon 6: 839 A>T, D195V. This mutation has been described previously in a FA patient and was associated with a milder clinical presentation (8). The FANCC mutation of the Hs766T cell line is identical to a mutation common in FA patients with a German ancestry and leads (in its homozygous form)

Received 1/16/03; accepted 3/19/03.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

2 Supported by NIH Specialized Programs of Research Excellence in Gastrointestinal Cancer CA62924.

3 To whom requests for reprints should be addressed. Phone: (410) 614-3314; Fax: (410) 614-9705. E-mail: sk@jhmi.edu.

4 The abbreviations used are: FA, Fanconi anemia; LOH, loss of heterozygosity.
to a relatively early onset of the disorder (9, 10). In addition to these homozygous mutations, one heterozygous mutation was observed in *FANCC* exon 14, 1813G/H11022A, E521K in cell line CAPAN2. This allele was confirmed to be expressed upon analysis of cDNA. No mutation was found in the other allele. The functional significance has not yet been determined; the mutation is not reported in FA patients or as a normal polymorphism.

These findings echo prior studies of *BRCA2* suggesting that low-penetrance mutant alleles, ones that are not uncommon among the unsuspecting general population, might also serve as a widespread

**Table 1** *Fanconi gene mutations in pancreatic cancer*

<table>
<thead>
<tr>
<th>Gene and setting</th>
<th>Mutations</th>
<th>LOH</th>
<th>Origin</th>
<th>Age (yrs)</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>BRCA2</em> (familial) (reference population)</td>
<td>17%</td>
<td>--</td>
<td>Inherited</td>
<td>66.0</td>
</tr>
<tr>
<td><em>BRCA2</em> (sporadic) (reference population)</td>
<td>7–10%</td>
<td>LOH</td>
<td>Usually inherited</td>
<td>71.5</td>
</tr>
<tr>
<td><em>FANCC</em> (sporadic)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PX19 tumor</td>
<td>D195V (GAT to GTT)</td>
<td>LOH</td>
<td>Inherited</td>
<td>44</td>
</tr>
<tr>
<td>PX102 tumor</td>
<td>Frameshift (CCTTAAA to CA)</td>
<td>LOH</td>
<td>Somatic</td>
<td>47</td>
</tr>
<tr>
<td>CAPAN2 cell line</td>
<td>E521K (GAG to AAG)</td>
<td>No LOH</td>
<td>Unknown</td>
<td>56</td>
</tr>
<tr>
<td><em>FANCG</em> (sporadic)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hs766T cell line</td>
<td>E105ter (GAG to TAG)</td>
<td>LOH</td>
<td>Probably inherited</td>
<td>46</td>
</tr>
</tbody>
</table>

*BRCA2* data are from Refs. 4–6. Average ages for *BRCA2* mutations include only inherited mutations. PX19 and PX102 had no family history of cancer by chart review. Variants present in the constitutional DNA were considered inherited.

LOH in tumors resulting in homozygosity for the mutation.

Functional significance unknown. --, not studied.

---

**Fig. 1.** Chromatograms of mutations identified in pancreatic cancers. All sequences depicted are from genomic DNA except for the CAPAN2 repeat, which represents cDNA sequence.
cause of an inherited risk of cancer among a population. “Sporadic” cancer is not always sporadic, an inconvenient but instructive terminological problem (4). The BRCA2 example is now extended by the tumor-associated mutations of FANCC and FANCG genes. The carrier rate of FA gene mutations has not been directly assessed but is estimated at 1 in 300 individuals in the general population (11), with higher rates in identifiable subpopulations.

Unlike BRCA2 mutations, which may not convey a decreased age of onset of pancreatic cancer (4, 6), the inherited FA gene mutations of Hs766T and tumor PX19 involved patients that are unusually young for pancreatic cancer (Table 1). Interestingly, the FANCC homozygous mutation in PX102, although of somatic origin, also affected a relatively young patient. The mutations here affected a third of the patients less than 50 years of age (three of nine patients) in our study population (samples of the remaining four young patients that lacked LOH were subsequently sequenced; no mutations were found). Both FANCC-mutant tumors were from nonsmokers. All four cases with sequence variants were otherwise histologically and genetically typical; they were ductal adenocarcinomas with aneuploidy and multiple genetic abnormalities known from prior studies (12). In the CDKN2A, KRAS2, TP53, and MADH4 genes, for example, the following changes are seen, respectively: in PX19, homozygous mutation, mutation, mutation, and homozygous deletion; in PX102, homozygous deletion, mutation, mutation, and mutation; in CAPAN2, mutation, mutation, wild-type, and wild-type; and in Hs766T, mutation, mutation, wild-type, and homozygous deletion.

FA proteins appear to be ubiquitously expressed among proliferating normal cells in culture. Fancc (558 amino acids; M, 63,000) and Fancg (622 amino acids; M, 68,000) proteins assemble together with Fanca, Fance, and Fancf proteins in a nuclear complex, which is believed to mediate the monoubiquitination of Fancd2 protein in response to DNA damage. Subsequently, Fancd2 is targeted to nuclear foci, the formation of which may involve Brc1 protein (13). BRC1+/− and BRC2−/− cells share mitomycin C hypersensitivity with all FA cells, and wild-type BRC2 restores resistance in BRC2−/− cells (1). The precise role of BRCA2 in the FA pathway has not yet been elucidated, but its BRC repeats are likely to serve as a scaffold for assembly of the RAD51 filament (14, 15). Mouse gene knockout models and the human disease of FA, however, indicate a potential difference between BRCA2 and other FA genes. Whereas the homozygous null state for most FA genes is not incompatible with live birth and viability, BRCA2-deficient cells appear to require retention of at least one conditional or hypomorphic allele to retain viability (16).

Breast cancers produced during the repair of mitomycin interstrand crosslinks may accumulate in the absence of an intact homologous repair system in cells deficient in members of the FA complex. Recently, Hs766T has indeed been found to be especially sensitive to mitomycin C as measured by p53 responses in a high-throughput compound screening system (17). Similar compound screening may identify other therapeutics specific for cells with such defects. It has been suggested that BRCA2-null tumors may offer an especially wide therapeutic window for the use of chemotherapeutic agents that require homologous recombination for their repair (3, 18, 19). Using therapies that included mitomycin, occasional complete remissions of pancreatic cancer have been reported (20–24), although the BRCA2 and FA gene status of such occasional patients has not been reported. A wide spectrum of hematological and nonhematological cancers has been reported in FA patients. However, FA patients have apparently not been observed to have an increased rate of pancreatic cancer (25, 26). Although other nonhematological malignancies are reported in such patients, most FA patients may not survive to an age highly susceptible to pancreatic cancer. It also remains possible that due to random variance in observations, the association could be missed in any general characterization of the Fanconi population but could be more easily seen in a focused study of pancreatic cancers. The relationship of pancreatic cancer to BRCA2 mutations, for example, is best seen in studies of pancreatic cancer families (6, 27). As another example, the high rate of pancreatic cancer in Peutz-Jeghers syndrome largely escaped notice until recently (28).

Additional study of FA genes is needed to determine possible mutations in other FA genes in pancreatic cancer or mutations in these genes among other tumor types. The stage at which FA mutations play a role in the initiation and progression of pancreatic cancer warrants investigation. Future clinical and preclinical studies should attempt to identify through genetic testing and optimize the therapeutic dosing of the subgroup of patients whose tumors contain FA defects (3).

Note Added in Proof

We recently identified additional homozygous variants in cell lines Su86.86 (FANCC.M350V, ATG to GTG, 57 y.o.) and CAPAN1 (FANCY, 7F7, TCT to TTT, 40 y.o.). Neither variant is reported in Fanconi anemia patients.

REFERENCES

17. Sohn, T. A., Bansal, R., Su, G. H., Murphy, K. M., and Kern, S. E. High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using


Fanconi Anemia Gene Mutations in Young-onset Pancreatic Cancer

Michiel S. van der Heijden, Charles J. Yeo, Ralph H. Hruban, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/63/10/2585

Cited articles
This article cites 28 articles, 9 of which you can access for free at:
http://cancerres.aacrjournals.org/content/63/10/2585.full.html#ref-list-1

Citing articles
This article has been cited by 39 HighWire-hosted articles. Access the articles at:
/content/63/10/2585.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.